Monopar Therapeutics, Inc. (MNPR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$117.56-0.84%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MNPR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -5.9% |
| Our one-year growth estimate | diamond | Not available |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
MNPR — earnings miss
Dated 2026-03-27
and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Why it matters: Positive data from this presentation could help ALXN1840's market position. It may also boost investor confidence.
Supportive ifResults show that ALXN1840 improves neurologic health more than standard care.
Worry ifResults do not show important improvement. They also do not raise safety issues.
Why it matters: Higher cash burn could signal financial strain. This may affect funding for ongoing projects and operations.
Worry ifCash burn for Q3 is reported below $6 million.
Less concerning ifCash burn exceeds $6 million for Q3.
Why it matters: Earnings results will show funding and health as the company gets ready to launch.
Watch forNet loss gets smaller or cash reserves grow a lot from past quarters.
Also watch forNet loss gets bigger or cash reserves drop a lot from past quarters.
Why it matters: More data on ALXN1840's effectiveness could help its market chance. It may also boost investor trust.
Supportive ifPresentation shows big improvements in liver health. Patients also report better quality of life.
Worry ifPresentation shows little or no change in liver health. There is also no change in quality of life.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$227 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $630 loss on $10,000 · 6.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,089 loss on $10,000 · 50.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Higher cash burn may raise worries about funding and staying in business.
Worry ifQuarterly cash burn is over $5 million. This shows higher costs than expected.
Less concerning ifCash burn is below $5 million, showing good cost management.
Why it matters: Updates on readiness show that ALXN1840 is ready for the market. This gives confidence in future sales.
Supportive ifThe company announces important hires or partnerships. These help with the launch readiness.
Worry ifNo big updates or hires are made for the launch of ALXN1840.
Why it matters: Positive results could increase ALXN1840's market potential and how investors feel.
Supportive ifResults from the EASL Congress show ALXN1840 helps liver disease and symptoms.
Worry ifFindings show no big gains compared to current treatments.
Why it matters: Funding updates are key for Monopar's growth plans. Investors want to see stability.
Supportive ifNew funding announced. This helps operations last until 2027.
Worry ifNo new funding announced. This raises worries about operations.
Why it matters: Earnings results will show how well the company is doing with money and operations.
Watch forEarnings show a smaller net loss than the previous quarter.
Also watch forEarnings report shows a larger net loss than the previous quarter.
Why it matters: FDA feedback is crucial for the approval process. Positive feedback can lead to quicker approval and market entry.
Supportive ifThe FDA gives good feedback on the NDA submission.
Worry ifThe FDA issues a complete response letter or significant concerns about the NDA.
Why it matters: A drop in sector revenue growth could impact Monopar's performance and funding.
Worry ifSector revenue growth is below its median for two months in a row.
Less concerning ifSector revenue growth remains above its median for the same period.
Why it matters: New data might show that ALXN1840 works better than standard care. This could change its market potential.
Supportive ifThe company shares new data. It shows big neurologic improvement from ALXN1840 at a major conference.
Worry ifNew data does not show big benefits compared to standard care.
Why it matters: Results may show that ALXN1840 works better than standard care. This could affect investor trust.
Supportive ifPositive results show big gains in nerve health and overall wellness.
Worry ifResults show no big changes compared to regular care.
Why it matters: Updates on funding are crucial for the company's plans through 2027.
Supportive ifManagement announces a new funding round or partnership that brings in at least $5 million.
Worry ifNo new funding or partnership announcements by the end of Q3 2026.
Why it matters: This earnings report will show if the company can maintain momentum after a recent earnings beat.
Watch forQ2 earnings report shows revenue growth above 10% year over year.
Also watch forQ2 earnings report shows revenue growth below 0% year over year.
Why it matters: Completing the NDA submission is key for ALXN1840's path to market. This could lead to regulatory approval and potential revenue.
Supportive ifThe company completes the NDA submission for ALXN1840 by the end of 2026.
Worry ifThe NDA submission is delayed beyond the expected timeline.
Why it matters: Good results from the Phase 3 trial would show ALXN1840 helps patients. This would help its market position.
Supportive ifThe Phase 3 trial shows big improvements in symptoms for Wilson disease patients.
Worry ifResults show no big improvements compared to the standard treatment.
Why it matters: Updates on the launch show ALXN1840 is ready for the market. This affects future revenue.
Supportive ifManagement announces key hires or partnerships. These will help ALXN1840 prepare for the market.
Worry ifNo updates or bad news about the launch plans.